324 related articles for article (PubMed ID: 3003561)
1. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
Laburthe M; Couvineau A; Rouyer-Fessard C
Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
[TBL] [Abstract][Full Text] [Related]
2. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
Waelbroeck M; Robberecht P; Coy DH; Camus JC; De Neef P; Christophe J
Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.
Robberecht P; Coy DH; Waelbroeck M; Heiman ML; de Neef P; Camus JC; Christophe J
Endocrinology; 1985 Nov; 117(5):1759-64. PubMed ID: 2994998
[TBL] [Abstract][Full Text] [Related]
4. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
Moretti C; Bagnato A; Solan N; Frajese G; Catt KJ
Endocrinology; 1990 Nov; 127(5):2117-26. PubMed ID: 2171907
[TBL] [Abstract][Full Text] [Related]
5. Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas.
Robberecht P; Waelbroeck M; Coy D; De Neef P; Camus JC; Christophe J
Peptides; 1986; 7 Suppl 1():53-9. PubMed ID: 3018703
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
RodrÃguez-Pena MS; Guijarro LG; Prieto JC
Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
[TBL] [Abstract][Full Text] [Related]
7. Ac-Tyr1hGRF discriminates between VIP receptors from rat liver and intestinal epithelium.
Rouyer-Fessard C; Couvineau A; Voisin T; Laburthe M
Life Sci; 1989; 45(9):829-33. PubMed ID: 2549322
[TBL] [Abstract][Full Text] [Related]
8. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
9. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
10. Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide.
Rorstad OP; Wanke I; Coy DH; Fournier A; Huang M
Mol Pharmacol; 1990 Jun; 37(6):971-7. PubMed ID: 2163020
[TBL] [Abstract][Full Text] [Related]
11. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.
Laburthe M; Amiranoff B; Boige N; Rouyer-Fessard C; Tatemoto K; Moroder L
FEBS Lett; 1983 Aug; 159(1-2):89-92. PubMed ID: 6307754
[TBL] [Abstract][Full Text] [Related]
12. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
Mittag TW; Tormay A; Podos SM
J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
[TBL] [Abstract][Full Text] [Related]
13. GRF is a highly potent activator of adenylate cyclase in the normal human, bovine and rat pituitary: interaction with somatostatin.
Reyl-Desmars F; Baird A; Zeytin FN
Biochem Biophys Res Commun; 1985 Mar; 127(3):977-85. PubMed ID: 2859017
[TBL] [Abstract][Full Text] [Related]
14. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.
Chakder S; Rattan S
J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560
[TBL] [Abstract][Full Text] [Related]
15. Rat hypothalamic GRF elicits its biologic action in GH3 cells by interaction with VIP- preferring receptor site(s).
Zeytin FN; Reyl-Desmars F; Rathbun T
Biochem Biophys Res Commun; 1985 Mar; 127(3):992-8. PubMed ID: 2985067
[TBL] [Abstract][Full Text] [Related]
16. Adrenocorticotropin, vasoactive intestinal polypeptide, growth hormone-releasing factor, and dynorphin compete for common receptors in brain and adrenal.
Li ZG; Queen G; LaBella FS
Endocrinology; 1990 Mar; 126(3):1327-33. PubMed ID: 1968378
[TBL] [Abstract][Full Text] [Related]
17. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in the goose cerebral cortex.
Zawilska JB; Niewiadomski P; Nowak JZ
Pol J Pharmacol; 2004; 56(2):203-11. PubMed ID: 15156071
[TBL] [Abstract][Full Text] [Related]
18. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
Pozo D; Montilla ML; Guerrero JM; Calvo JR
Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
[TBL] [Abstract][Full Text] [Related]
19. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
20. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
